A study to learn how safe KER-0193 is, the activity of KER-0193 in the body over a period of time, and the effect of KER-0193 to the body in adult healthy people taking single and multiple doses by the mouth that are increased a little at a time

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511468-94-00

Enrollment

Registered

2024-06-14

Start date

2024-07-10

Completion date

2024-12-26

Last updated

2024-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fragile X syndrome

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Belgium

None listed

Source: EU CTIS · Data processed: Feb 4, 2026